Introduction
therapy to mitigate flare effects. However, while AAs decrease flare incidence, they do not prevent it in all men [Crawford et al. 1989; Lunglmayr, 1989; Du Plessis, 1991; Thorpe et al. 1996] .
Any long-term impact of flare appears uncertain, with a lack of studies comparing long-term effects of flare protection versus no flare protection. Most available evidence relates to long-term use of AAs plus LHRH agonists in combined androgen blockade (CAB). Several studies have compared CAB using continuous AA plus LHRH agonist versus agonist monotherapy without AA flare protection [Crawford et al. 1989; Lunglmayr, 1989; Di Silverio et al. 1990; Du Plessis, 1991; Kotake et al. 1999; Noguchi et al. 2001] . While Crawford and colleagues showed that CAB achieved a significantly longer progression-free survival (PFS) and overall survival than LHRH agonist alone [Crawford et al. 1989 ], most of the other studies failed to show outcome benefits with CAB over agonist monotherapy. Four studies comparing CAB (LHRH agonist plus long-term AA) versus agonist 'monotherapy' with initial AA flare protection [Ferrari et al. 1993; Ferrari et al. 1996; Bono et al. 1998; De Voogt et al. 1998 ] also showed no difference in efficacy outcomes. However, the absence of prospective studies comparing initial AA flare protection versus no flare protection make it difficult to confirm the influence of initial flare protection on long-term outcomes.
Meta-analyses showed a small survival benefit for 5 years of treatment with CAB versus LHRH agonist monotherapy ± AA flare protection [Prostate Cancer Trialists' Collaborative Group, 2000; Samson et al. 2002] . A re-analysis of the Prostate Cancer Trialists' Group meta-analysis assessed the impact of disease flare by excluding trials without initial AA [Collette et al. 2001] . Analysis of 15 trials from the meta-analysis showed no significant survival benefit of CAB versus castration alone with initial AA flare protection. This may suggest a negative impact of disease flare on survival which does not occur when AA is given.
Gonadotrophin-releasing hormone (GnRH) antagonists have been developed, as an alternative to LHRH agonists to achieve effective longterm medical castration without the testosterone surge and associated flare risk. Unlike LHRH agonists, where the testosterone surge results from an initial intense receptor stimulation prior to downregulation/desensitization, GnRH antagonists directly block receptors, producing rapid testosterone suppression without an initial surge. The most extensively studied and widely available antagonist, degarelix, showed no evidence of testosterone surge or flare in clinical studies [Gittelman et al. 2008; Klotz et al. 2008; Van Poppel et al. 2008; Ozono et al. 2012] .
Recently, pooled analyses of data from prospective randomized phase III trials of degarelix versus LHRH agonists have reported increased prostatespecific antigen (PSA) PFS and survival [Klotz et al. 2014 ]; here we focus on data from patients treated with an AA in addition to a LHRH agonist in the 1-year trials. In the pivotal phase III trial (CS21), degarelix was as effective as the LHRH agonist leuprolide (± AA) at maintaining low testosterone levels over 1 year [Klotz et al. 2008] . A more recent large phase III trial (CS35) compared the efficacy and safety of 3-month dose regimens of degarelix and the LHRH agonist goserelin (± AA) over 1 year [Tombal et al. 2012] . Using pooled data from these two trials, we compared the efficacy outcomes of degarelix monotherapy versus combined LHRH agonist plus AA in PCa.
Patients and methods

Study designs and patients
Data were pooled from two prospective, randomized open-label 1-year clinical trials (CS21 and CS35) comparing degarelix with LHRH agonist (with or without AA) in patients with PCa. Both trials were performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Study protocols were approved by independent ethics committees and institutional review boards. All patients provided written informed consent.
Study CS21. The methodological details of study CS21 have been published [Klotz et al. 2008] . CS21 was a comparative study of degarelix versus leuprolide in patients (n = 610) with hormonenaïve adenocarcinoma of the prostate (any stage), a serum testosterone >1.5 ng/ml and a PSA >2 ng/ml, for whom endocrine treatment was indicated. Degarelix was administered as a monthly subcutaneous injection (240 mg for the first month followed by 12 maintenance doses of 80 or 160 mg). Leuprolide was administered as monthly intramuscular injections of 7.5 mg for 12 months. In the leuprolide group, the AA bicalutamide (50 mg once daily) was administered at the start of treatment for flare protection at the investigator's discretion; of those receiving AA flare protection, the majority (86%) received bicalutamide for ⩽28 days.
Study CS35. This was a comparative study of 3-month formulations of degarelix versus goserelin in hormone-naïve patients (n = 848) with PCa requiring androgen deprivation therapy. Degarelix was administered at a starting dose of 240 mg followed by 4 maintenance doses of 480 mg at months 1, 4, 7 and 10. Goserelin was administered at a starting dose of 3.6 mg of the 1-month implant followed by 4 doses of 10.8 mg of the 3-month implants at months 1, 4, 7 and 10. Bicalutamide was administered at the investigator's discretion as flare protection at the start of the goserelin treatment for a maximum of 28 days [Tombal et al. 2012] .
Statistical analyses
Patients in the LHRH agonist arm were considered to have received concomitant AA if treatment started in ⩽6 days of LHRH agonist treatment (n = 57). Two patients in the degarelix arm who received AA were excluded from the analysis. In total, 972 degarelix patients were included in the pooled analysis.
Median percentage change over time in testosterone and PSA for all patients is reported. Time to PSA PFS was defined as time to PSA failure or death, whichever was first. PSA failure was defined as 2 consecutive PSA increases of ⩾50% versus nadir and ⩾5 ng/ml on two consecutive measurements ⩾2 weeks apart.
Adjusted hazard ratios (HRs), 95% confidence intervals (CIs) and p values for PSA PFS failure were calculated using a Cox proportional hazards regression model. For analysis of all patients and patients with baseline PSA >20 ng/ml or >50 ng/ml, HRs were adjusted for baseline PSA (continuous), PCa stage and Gleason score; for estimates of mortality rates, age was an additional adjustment factor. To account for variations in risk factors across the patient population, a case-control analysis was performed using a conditional logistic regression model. Patients were matched according to baseline characteristics by stratifying by Gleason score (2-4, 5-6 and 7-10), disease stage (localized, locally advanced, metastatic and not classifiable) at enrolment and baseline PSA (⩽10, >10-20, >20-50 and >50 ng/ml).
Results
Patients
In the pooled CS21 and CS35 full analysis set populations (n = 1455), 972 patients received degarelix, 426 received LHRH agonist without AA, and 57 received LHRH agonist with AA. Baseline patient characteristics are summarized in Table 1 . The LHRH agonist + AA group contained a higher proportion of patients with Gleason score 7-10, metastatic disease or baseline PSA >50 ng/ml compared with the degarelix group; baseline PSA was also higher in the LHRH agonist + AA group and these characteristics were used for baseline adjustments as well as stratification in the case-control analysis.
Testosterone
The median percentage change in testosterone, during 13 months of treatment, was similar for degarelix and LHRH agonist + AA groups ( Figure 1a) . After 1 month, median testosterone was reduced by >90% in both groups and remained suppressed over the 13-month study periods. Median testosterone levels at day 364 were 0.11 (0.02-4.19) ng/ml and 0.07 (0.02-0.19) ng/ml for degarelix and LHRH agonist + AA groups respectively.
PSA
In the overall patient population, a rapid initial median reduction in PSA (~75% in the first month) was observed in patients receiving degarelix and those receiving a LHRH agonist + AA (Figure 1b) . PSA continued to fall in both groups and was suppressed around these low levels for the remainder of the study durations.
PSA PFS
The hazard ratio (HR) for PSA PFS failure for degarelix versus LHRH agonist + AA [adjusted for baseline PSA (continuous), PCa stage and Gleason score] was 0.56 (95% CI 0.33-0.97; p = 0.038). For the case-control analysis, only stratification levels with controls (did not fail PSA PFS criteria) and cases (PSA PFS failure) were included. This gave a total of 674 controls (637 and 37 treated with degarelix and LHRH agonist + AA, respectively) and 134 cases (119 and 15 treated with degarelix and LHRH + AA, respectively). When treated with degarelix compared with LHRH agonist + AA, there was a significantly lower odds ratio (OR) of PSA PFS failure for the overall population (OR = 0.42, 95% CI 0.20-0.89; p = 0.023) as well as for patients with baseline PSA >50 ng/ml (OR = 0.35, 95% CI 0.13-0.96; p = 0.042).
Survival
The Cox proportional hazards regression modeladjusted HR for overall mortality for degarelix versus LHRH agonist + AA for the all-patient cohort was 0.34 (95% CI 0.12-1.02; p = 0.055); adjusted for age, PCa stage, Gleason score and baseline PSA (continuous). The OR in the casecontrol analysis was 0.37 (95% CI 0.12-1.15; p = 0.085) (Figure 2 ).
Death occurred in 4 of 57 patients in the LHRH agonist + AA group and 18 of 972 patients in the degarelix group. Overall, only three patients were classified as having died from PCa, none of whom were in the LHRH agonist + AA group. The majority of deaths were classified as resulting from cardiovascular (CV) causes. The limited size of the LHRH agonist + AA group may restrict the detection of potential differences.
Discussion
EAU guidelines recommend AAs in the initial 2 weeks of LHRH agonist therapy to reduce clinical flare [Mottet et al. 2014] . However, our analysis suggests that 2 weeks of AA flare protection is associated with poorer outcomes than degarelix monotherapy. Thus, compared with LHRH agonist + AA, degarelix was associated with significantly higher PSA PFS in the overall population and in patients with baseline PSA >50 ng/ml. Our analysis showed a marked difference in baseline characteristics between treatment groups: the LHRH agonist + AA group had higher proportions of patients with Gleason score 7-10, metastatic disease or baseline PSA >50 ng/ml. These differences facilitate poorer prognosis, and less favorable outcomes, in the LHRH agonist + AA group. A case-control analysis was therefore used to stratify patients across treatment groups in terms of Gleason score, baseline PSA and PCa stage; conditional logistic regression allows investigation of the relationship between an outcome being an event (case) or not (control) with treatment (degarelix CI, confidence interval; OR, odds ratio; PSA PFS, prostate-specific antigen progression-free survival.
or LHRH + AA) as the only remaining variable to estimate.
In PCa, PSA recurrence often precedes clinically detectable recurrence by years and effective PSA control is associated with improved overall survival [Williams et al. 2004; Hussain et al. 2006; Hussain et al. 2009] . Any improvement in time to progression or death is clearly desirable and prolongation of PSA PFS by degarelix versus LHRH agonist + AA is likely to delay onset of castrateresistant disease.
Baseline disease stage and pretreatment PSA are associated with PCa outcome [Stock and Stone, 1997; D'amico et al. 2007] . In patients with metastatic disease, estimates suggest >90% will progress to androgen independence within 18-24 months [Petrylak, 2005] . In study CS21, patients at highest risk of PSA failure were those with advanced disease or baseline PSA >20 ng/ml [Tombal et al. 2010] . In our analyses, adjusted HRs showed significantly higher PSA PFS for degarelix in patients with baseline PSA >50 ng/ml.
The current analysis did not indicate a difference in mortality risk between degarelix and LHRH agonist + AA; the low number of deaths did not allow a robust comparison. Recent data have reported an increased risk of diabetes and certain CV diseases with LHRH agonist treatment [Levine et al. 2010] . In contrast, a pooled analysis of clinical trial data showed that degarelix dose and treatment duration were not independently associated with CV disease events [Smith et al. 2011] . More recently, another pooled analysis of degarelix comparative trials has shown that, in patients with a history of CV disease, degarelix was associated with a significantly lower risk (>50%) of subsequent CV event or death over 1-year of treatment compared with LHRH agonists [Albertsen et al. 2014] . The majority of deaths in the current study were due to CV causes (only three PCa deaths occurred in the degarelix group), but a potential difference between treatment with degarelix and LHRH agonist + AA in terms of overall survival and CV-related death requires confirmation with larger studies.
Limitations of this pooled analysis include the post hoc nature of the analysis, follow up of 1 year and the differences between the groups in terms of patient numbers and baseline characteristics, particularly the higher proportion of patients with metastatic disease in the LHRH agonist + AA group at baseline. However, when adjusted for confounding baseline factors and matched by baseline characteristics in a case-control analysis, the data indicate better PSA PFS with degarelix monotherapy compared with AA flare protection added to LHRH agonist during the first year of treatment. Thus, flare avoidance in patients at risk of PSA failure (e.g. high baseline PSA or metastatic disease) can be better achieved with GnRH antagonist monotherapy than with LHRH agonist plus AA, especially when evidence indicates that testosterone surge and flare effects can still occur when AAs are added to LHRH agonist therapy [Crawford et al. 1989; Kuhn et al. 1989; Klotz et al. 2008] .
cancer rarely show statistically significant differences. 
